Millennium Management LLC Grows Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Millennium Management LLC raised its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 1,008.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 411,072 shares of the company's stock after purchasing an additional 373,999 shares during the period. Millennium Management LLC owned 1.13% of iTeos Therapeutics worth $3,157,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Virtus ETF Advisers LLC increased its stake in shares of iTeos Therapeutics by 58.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock worth $69,000 after purchasing an additional 3,293 shares in the last quarter. Forefront Analytics LLC bought a new position in shares of iTeos Therapeutics in the fourth quarter valued at approximately $85,000. Graham Capital Management L.P. bought a new position in shares of iTeos Therapeutics in the fourth quarter valued at approximately $85,000. SG Americas Securities LLC boosted its position in shares of iTeos Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company's stock valued at $106,000 after acquiring an additional 1,508 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of iTeos Therapeutics by 16.9% in the fourth quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock valued at $128,000 after acquiring an additional 2,402 shares during the period. Hedge funds and other institutional investors own 97.16% of the company's stock.

iTeos Therapeutics Stock Performance

iTeos Therapeutics stock traded up $0.10 during mid-day trading on Wednesday, hitting $10.20. 691,769 shares of the company traded hands, compared to its average volume of 651,739. iTeos Therapeutics, Inc. has a one year low of $4.80 and a one year high of $18.13. The stock has a market cap of $390.39 million, a price-to-earnings ratio of -3.24 and a beta of 1.39. The stock has a fifty day moving average price of $7.20 and a 200-day moving average price of $7.44.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14. Sell-side analysts predict that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on ITOS. Leerink Partnrs lowered shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. HC Wainwright lowered shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, May 14th. Wells Fargo & Company restated an "equal weight" rating and issued a $12.00 price objective (down from $13.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 28th. Raymond James set a $12.00 price objective on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Finally, Piper Sandler restated an "overweight" rating and issued a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $15.86.

Insider Buying and Selling at iTeos Therapeutics

In other iTeos Therapeutics news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the transaction, the insider now directly owns 3,452,797 shares of the company's stock, valued at approximately $27,829,543.82. The trade was a 23.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the transaction, the insider now directly owns 2,108,594 shares in the company, valued at approximately $16,995,267.64. The trade was a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 12.50% of the company's stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.